作者: Julie Earl , Sandra Garcia-Nieto , Jose Carlos Martinez-Avila , José Montans , Alfonso Sanjuanbenito
DOI: 10.1186/S12885-015-1779-7
关键词: Stem cell 、 Pancreatic cancer 、 Pathology 、 Exocrine pancreatic cancer 、 Internal medicine 、 Oncology 、 Surgical oncology 、 Circulating tumor cell 、 Disease 、 Medicine 、 Survival rate 、 KRAS
摘要: Background Pancreatic cancer remains one of the most difficult cancers to treat with poorest prognosis. The key improving survival rates in this disease is early detection and monitoring disseminated residual disease. However, hindered due lack reliable diagnostic predictive markers which mean that majority patients succumb their condition within a few months.